| HDL from an Alzheimer's disease perspective |
20 |
| Sex differences in metabolism and cardiometabolic disorders |
19 |
| Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism |
19 |
| Classical and alternative roles for autophagy in lipid metabolism |
18 |
| RNA-targeted therapeutics for lipid disorders |
14 |
| Polygenic influences on dyslipidemias |
14 |
| New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk |
14 |
| New insights in the multiple roles of bile acids and their signaling pathways in metabolic control |
13 |
| The lysophosphatidic acid acyltransferases (acylglycerophosphate acyltransferases) family: one reaction, five enzymes, many roles |
12 |
| Metabolism: The road to inflammation and atherosclerosis |
11 |
| Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application |
11 |
| Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis |
11 |
| Long noncoding RNAs in lipid metabolism |
11 |
| Atherosclerosis in the single-cell era |
10 |
| LDL and foam cell formation as the basis of atherogenesis |
10 |
| The evolution of genetic-based risk scores for lipids and cardiovascular disease |
9 |
| Role of serum amyloid A in atherosclerosis |
8 |
| Brown adipose tissue and lipid metabolism |
8 |
| Lysosomal acid lipase and lipid metabolism: new mechanisms, new questions, and new therapies |
8 |
| Colchicine: an affordable anti-inflammatory agent for atherosclerosis |
8 |
| Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all? |
7 |
| Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors? |
7 |
| Fibroblast growth factor-transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis |
7 |
| The biochemical and genetic diagnosis of lipid disorders |
7 |
| Pathways of smooth muscle foam cell formation in atherosclerosis |
7 |
| Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2 |
7 |
| Effects of exercise on HDL functionality |
7 |
| Metformin, lipids and atherosclerosis prevention |
6 |
| Lipid-driven immunometabolic responses in atherosclerosis |
6 |
| Metabolism of innate immune cells: impact on atherosclerosis |
6 |
| Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis |
6 |
| Monocytes and macrophages in atherogenesis |
6 |
| DNA methylation in human lipid metabolism and related diseases |
6 |
| Role of DNA copy number variation in dyslipidemias |
6 |
| Role of sortilin in lipid metabolism |
6 |
| Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell? |
6 |
| Regulation of lipid rafts, angiogenesis and inflammation by AIBP |
5 |
| Progress in finding pathogenic DNA copy number variations in dyslipidemia |
5 |
| From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants |
5 |
| Intestinal lymphatic vessels and their role in chylomicron absorption and lipid homeostasis |
5 |
| Monogenic, polygenic, and oligogenic familial hypercholesterolemia |
5 |
| HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease |
5 |
| The optimal time of day for statin administration: a review of current evidence |
4 |
| The potential of chronopharmacology for treatment of atherosclerosis |
4 |
| Chylomicron retention disease: genetics, biochemistry, and clinical spectrum |
4 |
| Lipoprotein metabolism in liver diseases |
4 |
| Unexplained reciprocal regulation of diabetes and lipoproteins |
4 |
| Cholesterol transfer at endosomal-organelle membrane contact sites |
4 |
| Microbiota and HDL metabolism |
4 |
| The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation |
3 |
